Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 2, 2009, Pages 163-168

  Adamopoulos, Adam B ^a   Sakizlis, George N ^a   Nasothimiou, Efthimia G ^a   Anastasopoulou, Ioanna ^b   Anastasakou, Eugenia ^c   Kotsi, Paraskevi ^b   Karafoulidou, Anastasia ^b   Stergiou, George S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Aspirin; Lansoprazole; Platelet Aggregation; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; PEPSINOGEN I; PROTON PUMP INHIBITOR; SALICYLIC ACID; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ATTENUATION; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENTERIC COATED TABLET; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS;

EID: 74249102181     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181af6d9c     Document Type: Article

References (37)

1. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
2. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-718.
3. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
4. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-1416.
5. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16:1945-1953.
6. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-830.
7. American Gastroenterological Association; Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4: 1082-1089.
8. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328-346.
9. Antman EM, Bennett JS, Daugherty A, et al; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
10. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
11. Lichtenberger LM, Ulloa C, Romero JJ, et al. Nonsteroidal antiinflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology. 1996;111:990-995.
12. Giraud MN, Sanduja SK, Felder TB, et al. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther. 1997;11:899-906.
13. 13. Iñarrea P, Esteva F, Cornudella R, et al. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol. 2000;35:242-246.
14. Dupont I, Berthou F, Bodenez P, et al. Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos. 1999;27:322-326.
15. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50: 1822-1834.
16. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost. 2008;99:14-26.
17. Ibáñez L, Vidal X, Vendrell L, et al; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235-242.
18. Fernández-Fernández FJ. Might proton pump inhibitors prevent the antiplatelet effects of low- or very low-dose aspirin? Arch Intern Med. 2002;162:2248.
19. Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963-978.
20. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801-1833.
21. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 1997; 24:65-70.
22. Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther. 2003;17: 361-367.
23. Freston JW, Kukulka MJ, Lloyd E, et al. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther. 2004;20:407-411. (Pubitemid 39120251)
24. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica. 2004;34: 415-427. (Pubitemid 38901452)
25. Bowen WP, Carey JE, Miah A, et al. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos. 2000;28: 781-788.
26. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
27. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509.
28. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157: 148.e1-e5.
29. Kim KA, Kim MJ, Park JY, et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2003;31:1227-1234.
30. Katsuki H, Hamada A, Nakamura C, et al. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol. 2001;57:709-715.
31. Severino G, Chillotti C, De Lisa R, et al. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39:162-164.
32. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol. 1996;8(Suppl 1):S21-S25.
33. Burke A, Smyth E, FitzGerald GA. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006:687-690.
34. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206-1211.
35. Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Low-dose entericcoated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med. 1986;108:616-621.
36. Cerletti C, Marchi S, Lauri D, et al. Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans. Clin Pharmacol Ther. 1987;42: 175-180.
37. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: 494-502.